A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Event-driven Phase 3 Study to Investigate the Safety and Efficacy of Finerenone, in Addition to Standard of Care, on the Progression of Kidney Disease in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease
Phase of Trial: Phase III
Latest Information Update: 27 Sep 2017
At a glance
- Drugs Finerenone (Primary)
- Indications Diabetic nephropathies; Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms FIDELIO-DKD
- Sponsors Bayer
- 08 May 2017 Planned End Date changed from 28 May 2019 to 28 Oct 2019.
- 08 May 2017 Planned primary completion date changed from 29 Apr 2019 to 29 Sep 2019.
- 01 Oct 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.